Cargando…

Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week

BACKGROUND: MK-8507 is a novel HIV-1 non-nucleoside reverse transcriptase inhibitor being developed for treatment of HIV-1 infection. MK-8507 has high antiviral potency in vitro and pharmacokinetic (PK) properties that support once-weekly dosing. SETTING: A phase 1, open-label, proof-of-concept stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schürmann, Dirk, Jackson Rudd, Deanne, Schaeffer, Andrea, De Lepeleire, Inge, Friedman, Evan J., Robberechts, Martine, Zhang, Saijuan, Liu, Yang, Kandala, Bhargava, Keicher, Christian, Däumer, Martin, Hofmann, Jörg, Grobler, Jay A., Stoch, S. Aubrey, Iwamoto, Marian, Ankrom, Wendy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JAIDS Journal of Acquired Immune Deficiency Syndromes 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740605/ https://www.ncbi.nlm.nih.gov/pubmed/34654041 http://dx.doi.org/10.1097/QAI.0000000000002834

Ejemplares similares

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
por: Ankrom, Wendy, et al.
Publicado: (2021)

Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Nonnucleoside Reverse Transcriptase Inhibitor
por: Gillespie, Gillian, et al.
Publicado: (2021)

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV
por: Matthews, Randolph P., et al.
Publicado: (2021)

A phase 1, open‐label study to evaluate the drug interaction between islatravir (MK‐8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females
por: Ankrom, Wendy, et al.
Publicado: (2021)

551. MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Ethinyl Estradiol and Levonorgestrel
por: Ankrom, Wendy, et al.
Publicado: (2018)

A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV
por: Matthews, Randolph P., et al.
Publicado: (2021)

A Phase 1 Trial to Evaluate the Relationship Between Fluoride Intake and Urinary Fluoride Excretion in Healthy Participants
por: Gillespie, Gillian, et al.
Publicado: (2021)

546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
por: Matthews, Randolph, et al.
Publicado: (2018)

Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions
por: Khalilieh, Sauzanne, et al.
Publicado: (2020)

Lack of a Clinically Meaningful Drug Interaction Between the HIV‐1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate
por: Rudd, Deanne Jackson, et al.
Publicado: (2021)

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin
por: McCrea, Jacqueline B., et al.
Publicado: (2021)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
por: Ariën, Kevin K, et al.
Publicado: (2011)

Mitochondrial toxicities of nucleoside analogue reverse transcriptase inhibitors in AIDS cases
por: Marfatia, Yogesh S., et al.
Publicado: (2014)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
por: Famiglini, Valeria, et al.
Publicado: (2016)

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
por: Vanangamudi, Murugesan, et al.
Publicado: (2023)

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan
por: Wu, Pei-Ying, et al.
Publicado: (2017)

NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities
por: Thammaporn, Ratsupa, et al.
Publicado: (2015)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review
por: Rutherford, George W., et al.
Publicado: (2016)

A Model‐Informed Drug Discovery and Development Strategy for the Novel Glucose‐Responsive Insulin MK‐2640 Enabled Rapid Decision Making
por: Visser, Sandra A.G., et al.
Publicado: (2020)

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance
por: Galilee, Meytal, et al.
Publicado: (2018)

Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors—In Silico Activity Prediction
por: Dąbrowska, Aleksandra, et al.
Publicado: (2018)

Nucleoside Analog Reverse-Transcriptase Inhibitors in Membrane Environment: Molecular Dynamics Simulations
por: Stachowicz-Kuśnierz, Anna, et al.
Publicado: (2023)

The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors
por: Fernandes, Lívia da Rocha, et al.
Publicado: (2023)

Pelvic irradiation does not increase the risk of hip replacement in patients with gynecological cancer: A cohort study based on 8,507 patients
por: Dybvik, Eva, et al.
Publicado: (2014)

Nucleoside Analogue Reverse Transcriptase Inhibitors Differentially Inhibit Human LINE-1 Retrotransposition
por: Jones, R. Brad, et al.
Publicado: (2008)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
por: Schauer, Grant, et al.
Publicado: (2013)

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability
por: Usach, Iris, et al.
Publicado: (2013)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
por: Wright, David W., et al.
Publicado: (2012)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
por: Himmel, Daniel M., et al.
Publicado: (2020)

Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
por: Zhuang, Chunlin, et al.
Publicado: (2020)

Prodrugs of γ‐Alkyl‐Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase
por: Zhao, Chenglong, et al.
Publicado: (2020)

Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency
por: Matthews, Randolph P., et al.
Publicado: (2022)

Abstracts from the current global literature: Mitochondrial toxicities due to nucleoside reverse transcriptase inhibitors
por: Jain, Sonia, et al.
Publicado: (2012)

The Lysine 65 Residue in HIV-1 Reverse Transcriptase Function and in Nucleoside Analog Drug Resistance
por: Garforth, Scott J., et al.
Publicado: (2014)

Nucleoside reverse transcriptase inhibitor-induced rat oocyte dysfunction and low fertility mediated by autophagy
por: Tang, Li, et al.
Publicado: (2017)

Novel Thiazolidin-4-ones as Potential Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
por: Petrou, Anthi, et al.
Publicado: (2019)

Synthesis and molecular docking studies of quinoline derivatives as HIV non-nucleoside reverse transcriptase inhibitors
por: BHARDWAJ, Nivedita, et al.
Publicado: (2020)

Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV
por: De Francesco, Davide, et al.
Publicado: (2021)

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants
por: Dwivedi, Richa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2cutdu9kve8hh7ovksoqjf77ob